Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 9/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6417487 | 0.99 | HDAC11 (0.37) | HDAC11HCRTR1HCRTR2CCR5ACACB | |
| SCHEMBL6410745 | 0.91 | HDAC11 (0.36) | HDAC11CCR5AVPR1BAKT1ROCK2 | |
| Hydrochloric Acid SCHEMBL6413751 | 0.91 | HDAC11 (0.36) | HDAC11CCR5AVPR1BAKT1ROCK2 | |
| SCHEMBL6409712 | 0.90 | POLB (0.40) | HCRTR1HCRTR2CCR5 | |
| SCHEMBL6417273 | 0.90 | HDAC11 (0.37) | HDAC11CCR5AKT1ROCK2ROCK1 | |
| SCHEMBL6410716 | 0.90 | CCR5 (0.38) | HDAC11HCRTR1HCRTR2CCR5AVPR1B | |
| SCHEMBL6410286 | 0.90 | HDAC11 (0.38) | HDAC11HCRTR1HCRTR2CCR5ROCK2 | |
| Hydrochloric Acid SCHEMBL6409854 | 0.90 | POLB (0.39) | HCRTR1HCRTR2CCR5 | |
| Hydrochloric Acid SCHEMBL6408691 | 0.90 | ROCK2 (0.41) | CCR5ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL6409812 | 0.89 | CCR5 (0.37) | HDAC11HCRTR1HCRTR2CCR5AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | HDAC11 431/4885HCRTR1 121/4885HCRTR2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.